Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

e accounts receivable 5,365 7,597 Decrease (increase) in inventories (4,073) 1,160 Decrease (increase) in prepaids and other assets 496 2,044 Increase (decrease) in accounts payable (8,095) (2,033) Increase (decrease) in accrued compensation (6,133) (3,932) Increase (decrease) in accrued clinical trial expenses (2,640) 86 Increase (decrease) in accrued expenses to contract manufacturers - (31,994) Increase (decrease) in accrued expenses 3,364 (123) Increase (decrease) in deferred revenue (3,029) (1,200) Increase (decrease) in other liabilities (1,897) (2,761) ------ ------ Net cash used in operating activities (42,394) (64,972) Cash flows from investing activities: Purchases of property and equipment (5,104) (5,281) Purchases of investments (85,298) (156,092) Maturities of investments 104,458 186,758 Transaction costs from Novartis pulmonary asset sale (4,766) - ------ --- Net cash provided by investing activities 9,290 25,385 Cash flows used in financing activities: Proceeds from issuances of common stock 61 371 Payments of loan and capital lease obligations (302) (411) ---- ---- Net cash used in financing activities
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... the Best in the Nation ,, PHILADELPHIA, ... announces it has been granted Magnet(R) recognition by ... Program(R). Magnet(R) is one of the highest levels ... achieve, and places Hahnemann among the five percent ... this prestigious distinction. ,, At 9:00 am on ...
(Date:12/16/2009)... Resources, one of the world,s leading research and ... that, according to responses from surveyed dermatologists, Centocor ... inhibitors) will capture 22 percent of the biologics ... moderate to severe psoriasis. Among these two agents, ... times as much patient share as briakinumab. ...
(Date:12/16/2009)... supplement? InVitria has what scientists have been asking for! Zap-CHO ... the growth and productivity of CHO cells. Developed for scientists ... free, well defined and consistent recombinant CHO supplement. , ... ... 2009 -- Scientists working with CHO cells can now access ...
(Date:12/15/2009)... -- Epeius Biotechnologies Corporation, an emerging leader in ... validation of the cutting-edge science behind its lead ... the world rediscovered the Cyclin G1 gene ... pathogenesis and disease progression, and thus a prime ... NIH National Cancer Institute investigating the role of ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
... with potential Benitec HIV therapy, MELBOURNE, Australia, Aug ... of Understanding with California-based,CalbaTech, Inc. (OTC Bulletin Board: CLBE) ... who may use the healthy adult (or "blood" or,"hematopoietic") ... with City of Hope, a biomedical research and,treatment center, ...
... Avicena Group,Inc. (OTC Bulletin Board: AVGO), a late-stage ... neurodegenerative diseases,announced today that Chief Executive Officer Dr. ... ongoing product development,programs at 1:30 EDT on August ... at the Charleston Place Hotel in Charleston, S.C. ...
... Number and Viability of Stem Cells Derived from ... Patented Preservation Media, BOTHELL, Wash., Aug. 17 ... and marketer of,proprietary hypothermic storage and cryopreservation media products ... the exclusive,supplier of preservation media to the New England ...
Other Biology Technology:Benitec MOU With CalbaTech, Inc. 2Benitec MOU With CalbaTech, Inc. 3Benitec MOU With CalbaTech, Inc. 4Avicena Group to Present at Noble Financial Conference 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 3
(Date:12/16/2009)... 8, 2009 National Instruments (Nasdaq: ... measurement and control, and DENSO Robotics, a ... robotics technology, today announced their collaboration to ... DENSO robotic arms. The collaboration increases productivity ... flexible manufacturing applications. In today,s trend toward ...
(Date:12/16/2009)... CHURCH, Va., Dec. 9 CSC ... that the American Association for Laboratory Accreditation ... Commission (ISO/IEC) 17025:2005 accreditation to the company,s ... CSC Identity Labs located in Fairmont, W.Va. ... test laboratory in the world to achieve ...
(Date:12/15/2009)... The 2009 Frost & Sullivan European Border ... Sagem Securite (Safran Group) for its innovative ... the company,s expertise in advanced biometric technology ... value-added products to end users. ,, ... Securite has been involved in delivering identification ...
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Benevolence Beyond Politics Inc Announces Position to Provide Financial and Logistical Support for Humanitarian and Medical Missions Worldwide 6372 1Benevolence Beyond Politics Inc Announces Position to Provide Financial and Logistical Support for Humanitarian and Medical Missions Worldwide 6372 2Merz Pharmaceuticals Announces Approval of Post stroke Upper Limb Spasticity Indication for Xeomin 28R 29 in the EU 6368 1Merz Pharmaceuticals Announces Approval of Post stroke Upper Limb Spasticity Indication for Xeomin 28R 29 in the EU 6368 2Merz Pharmaceuticals Announces Approval of Post stroke Upper Limb Spasticity Indication for Xeomin 28R 29 in the EU 6368 3Merz Pharmaceuticals Announces Approval of Post stroke Upper Limb Spasticity Indication for Xeomin 28R 29 in the EU 6368 4Results From Two Phase II Trials Add to Understanding of Ticagrelor 28BRILINTA 28TM 29 29 and How it Works in the Body 6364 1Results From Two Phase II Trials Add to Understanding of Ticagrelor 28BRILINTA 28TM 29 29 and How it Works in the Body 6364 2Results From Two Phase II Trials Add to Understanding of Ticagrelor 28BRILINTA 28TM 29 29 and How it Works in the Body 6364 3Results From Two Phase II Trials Add to Understanding of Ticagrelor 28BRILINTA 28TM 29 29 and How it Works in the Body 6364 4
... tomatoes to grow purple tomatoes high in health-protecting ... at particularly high levels in berries such as ... to increase the levels of health-promoting compounds in ... people do not eat 5 portions of fruits ...
... Rockot launcher that shall carry ESA,s GOCE Earth Explorer ... failure in the guidance and navigation system of the ... discovered during the spacecraft,s launch preparation tests on 7 ... postponement of the launch. , The cause of the ...
... Researchers at the Heidelberg University Hospital have discovered a new ... a protective component of the bile is missing, the liver ... resulting in cirrhosis of liver, a transformation of liver cells ... This could explain some of the cases of liver cirrhosis ...
Other Biology News:Fried purple tomatoes 2Toxic bile damages the liver 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... cells were cultured in RPMI 1640 with 2 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Biology Products: